-
1 week ago | 
cgtlive.com | Saurabh Dahiya |Noah Stansfield |Ashling Wahner |Caroline Seymour
At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, Galapagos presented new data regarding GLPG5101, an investigational. CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy product. During the conference, CGTLive® interviewed Omotayo Fasan, MRCP, DTM&H, MBBS, the head of the clinical development program at Galapagos, about the findings.
-
1 week ago | 
cgtlive.com | Saurabh Dahiya |Noah Stansfield |Ashling Wahner |Caroline Seymour
At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, data are being presented from a phase 1 clinical trial (NCT04989803) evaluating Kite's KITE-363, a dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with relapsed/refractory (r/r) B-cell lymphoma.
-
2 weeks ago | 
cgtlive.com | Saurabh Dahiya |Ashling Wahner |Caroline Seymour
This video originally appeared on our sister site, OncLive®. At the highest dose level in CAR naive patients, we observed an objective overall response rate of 87% and a complete remission rate of 78%. Kite's KITE-363, a dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, is currently being evaluated for the treatment of relapsed/refractory (r/r) B-cell lymphoma in a phase 1 clinical trial (NCT04989803).
-
Jan 25, 2025 | 
targetedonc.com | Caroline Seymour
Data from the phase 2 ASCEND trial (NCT05042128) showed that adding the novel cyclic peptide certepetide to gemcitabine and nab-paclitaxel (Abraxane) demonstrated signs of efficacy but did not improve progression-free survival (PFS) compared with chemotherapy alone in patients with untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Findings were presented at the 2025 Gastrointestinal Cancers Symposium.
-
Jan 24, 2025 | 
targetedonc.com | Caroline Seymour
Adding tislelizumab to a combination of irinotecan, paclitaxel, oxaliplatin, and 5-fluorouracil/leucovorin (POFI) showed effectiveness and a manageable safety profile as a frontline treatment for patients with advanced, HER2-negative, mismatch repair–proficient gastric and gastroesophageal junction (GEJ) adenocarcinoma. These findings from the phase 1/2 SYLT-023 trial (NCT05319639) were presented at the 2025 Gastrointestinal Cancers Symposium.
-
Jan 24, 2025 | 
cancernetwork.com | Caroline Seymour
The addition of the anti-PD-1 antibody tislelizumab to the standard-of-care chemotherapy regimen of irinotecan, paclitaxel, oxaliplatin, and 5-fluorouracil/leucovorin (POFI) demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, HER2-negative, mismatch repair–proficient gastric and gastroesophageal junction adenocarcinoma, according to data from the phase 1/2 SYLT-023 trial (NCT05319639) presented at the 2025 ASCO Gastrointestinal Cancer Symposium.
-
Jan 12, 2025 | 
targetedonc.com | Caroline Seymour
THE FIRST-IN-CLASS, SELECTIVE, dual T-cell agonist invikafusp alfa had a 50% disease-control rate (DCR) in patients with heavily pretreated anti–PD-1/PD-L1–resistant solid tumors, according to findings presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting in Houston, Texas.1 Data from the phase 1/2 START-001 trial (NCT05592626) compared favorably with the 32% DCR seen with prior anti–PD-L1 therapy across all dose cohorts.
-
Dec 11, 2024 | 
cancernetwork.com | Caroline Seymour
Among patients with relapsed/refractory follicular lymphoma, combining tafasitamab-cxix (Monjuvi) with lenalidomide (Revlimid) and rituximab (Rituxan) significantly prolonged progression-free survival (PFS) vs lenalidomide/rituximab alone, according to primary data from the phase 3 inMIND trial (NCT04680052) presented at the 2024 American Society of Hematology Annual Meeting & Exposition (ASH).1 At a median follow-up of 14.1 months, the median investigator-assessed progression-free survival...
-
Dec 10, 2024 | 
targetedonc.com | Caroline Seymour
Adding tafasitamab-cxix (Monjuvi) to lenalidomide (Revlimid) and rituximab (Rituxan) significantly improved progression-free survival (PFS) in patients with relapsed/refractory follicular lymphoma, according to findings from the phase 3 inMIND trial (NCT04680052).1 Results presented at the 2024 ASH Annual Meeting showed that at a median follow-up of 14.1 months, the median investigator-assessed PFS was 22.4 months (95% CI, 19.2-not evaluable [NE]) with the triplet (n = 273) vs 13.9 months...
-
Dec 10, 2024 | 
cancernetwork.com | Caroline Seymour
For patients with relapsed or refractory BTK-naive mantle cell lymphoma, brexucabtagene autoleucel (brexu-cel; Tecartus) generated high objective response rates (ORR) despite high-risk features like TP53 mutations, as shown by results from cohort 3 of the phase 2 ZUMA-2 trial (NCT04880434).1 Findings that were presented at the 2024 American Society of Hematology Annual Meeting & Exposition (ASH) with a median follow-up of 15.5 months (range, 5-15) indicated that the ORR was 91%, (95% CI,...
